TODAY'S MARKET INTELLIGENCE
Huiyu Pharmaceutical's HY07121 Injection Gets Clinical Trial Approval
English summary
Huiyu Pharmaceutical's wholly-owned subsidiary Huiyu Haiyue received the clinical trial approval notice from the NMPA for HY07121 injection (subcutaneous) to treat advanced solid tumors. The drug is an anti-PD-1, anti-TIGIT, IL-15/IL-15Rα triple-target antibody fusion protein, a Class 1 innovative therapeutic biologic. This marks progress in the company's innovative R&D pipeline.
The English text is machine translated and may require verification against the Chinese version.
Browse today's intelligence